Merck Animal Health announced the U.S. Food and Drug Administration (FDA) approval of Bravecto Quantum (fluralaner for extended-release injectable suspension) – a once-yearly injectable product to treat and protect dogs from fleas and ticks. The product is expected to be available at veterinary clinics and hospitals nationwide by August 2025. 

Bravecto Quantum was first approved in Australia and New Zealand in 2023, followed by the European Union (EU) in 2024 and now the U.S. in 2025. It is currently approved in more than 50 countries. 

“We take pride in our leadership in long-acting preventative parasiticides and are offering an option that gives dogs year-round protection from fleas and ticks in one injection administered by a veterinarian,” said Christine Royal, DVM, vice president, companion animal and equine business unit, Merck Animal Health. 

“The approval of Bravecto Quantum provides veterinarians and pet owners with a safe and effective option for flea and tick protection for dogs.” 

Bravecto Quantum kills adult fleas and is indicated for the treatment and prevention of flea infestations and for the treatment and control of tick infestations. 

“Though people often think of flea and tick season during the summer months, studies have shown that fleas and ticks are most active from early spring through the fall, and can be a threat year-round,” said Frank Guerino, Ph.D., associate vice president of Global Pharmaceutical Development, Merck Animal Health. “With Bravecto Quantum, a single dose provides year-long protection, simplifying care for pet owners and veterinarians, and promoting compliance.”